<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>15</Volume>
				<Issue>21</Issue>
				<PubDate PubStatus="epublish">
					<Year>2014</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Extended use of P504S Positive Primary Circulating Prostate Cell Detection to Determine the Need for Initial Prostate Biopsy in a Prostate Cancer Screening Program in Chile</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>9335</FirstPage>
			<LastPage>9339</LastPage>
			<ELocationID EIdType="pii">30072</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; To determine the frequency of primary circulating prostate cells (CPC) detection accordingto age and serum PSA levels in a cohort of men undergoing screening for prostate cancer and to determinethe diagnostic yield in those men complying with the criteria for prostate biopsy. Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: Aprospective study was carried out to analyze all men evaluated in a hospital prostate cancer screening program.Primary CPCs were obtained by differential gel centrifugation and detected using standard immunocytochemistryusing anti-PSA, positive samples undergoing a second process with anti-P504S. A malignant primary CPC wasdefined as PSA+ P504S+, and a test positive if 1 cell/4ml was detected. The frequency of primary CPC detectionwas compared with age and serum PSA levels. Men with a PSA &gt;4.0ng/ml and/or abnormal rectal examinationunderwent 12 core prostate biopsy, and the results were registered as cancer/no-cancer and compared with thepresence/absence of primary CPCs to calculate the diagnostic yield. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: A total of 1,117 men participated;there was an association of primary CPC detection with increasing age and increasing serum PSA. Some 559 menunderwent initial prostate biopsy of whom 207/559 (37.0%) were positive for primary CPCs and 183/559 (32.0%)had prostate cancer detected. The diagnostic yield of primary CPCs had a sensitivity of 88.5%, a specificity of88.0%, and positive and negative predictive values of 78.3% and 94.9%, respectively. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: The use ofprimary CPCs for testing is recommended, since its high negative predictive value could be used to avoid prostatebiopsy in men with an elevated PSA and/or abnormal DRE. Men positive for primary CPCs should undergoprostate biopsy. It is a test that could be implemented in the routine immunocytochemical laboratory.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Prostate cancer screening</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">primary circulating prostate cells</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">diagnostic yield</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_30072_23fbf6d640ca61506d807f10d8b34d88.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
